

Cover Story
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for February 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - $180M in NCI grants have been terminated by Trump administration, systematic review finds